Cancer researchers reported a next-generation engineered therapy that combines bacterial tumor targeting with nutrient deprivation and immune stimulation in a single construct. In experiments described with Salmonella-mediated tumor therapy, an engineered conjugate linking L-asparaginase and flagellin to a calreticulin-targeting system improved antitumor effectiveness. The approach leans on calreticulin-bearing cancer cell surfaces (calreticulin is used as a “eat-me” signal in immunology contexts) to localize activity, while flagellin boosts immune signaling. The work adds to a growing engineering playbook for oncolytic or bacteria-derived strategies that seek to concentrate cytotoxic function and immune activation in the tumor microenvironment.